Additive effects of isoniazid preventive therapy and HAART

AIDS

Volumn 23, Issue 11, 2009, Pages 1446-1447

  Golub, Jonathan E ^a,b   Chaisson, Richard E ^a,b   Martinson, Neil A ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; AZITHROMYCIN; COTRIMOXAZOLE; ISONIAZID;

CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DRUG POTENTIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SOUTH AFRICA; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; EPIDEMIOLOGIC METHODS; HUMANS; ISONIAZID; TUBERCULOSIS;

EID: 68449088878     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832d53fc     Document Type: Letter

References (5)

1. Wood R, Lawn SD, Bekker LG. Are the effects of isoniazid preventive therapy and HAART additive in preventing of HIV-associated tuberculosis? AIDS 2009; 23:1444-1446.
2. Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, et al. Isonaizid preventive therapy, HAART and tuberculosis in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009; 23:631-636.
3. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004; 1:CD000171.
4. WHO. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009. WHO/HTM/TB/2009.411. Geneva: World Health Organization, 2009.
5. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, Ki ng BS, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21:1441-1448.